Ravimine Pharma Private Limited
About Ravimine Pharma Private Limited
Data last updated:
Ravimine Pharma Private Limited is a private limited company based in Muzaffarpur, Bihar, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 January 2018 and has been in existence for over 8 years.
The company is registered with the Registrar of Companies (ROC), Patna, under CIN U74999BR2018PTC036999. Its GSTIN is 10AAICR7403H1ZP (Bihar).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹10 Lakh. It is led by directors Sippy Shawarna and Meera Kumari.
Its last annual general meeting (AGM) was held on 30 September 2023, and its latest financial statements are for the year ended 31 March 2023. The registered office is at Maripur Muzaffarpur 1 Muzaffarpur Bihar India, Bihar, India – 842003.
As per the financials filed for FY 2023, the company reported a revenue of ₹10.92 Lakh, a growth of 60% compared to the previous year. For the same year it recorded a net profit of ₹5,707 (net margin 0.5%) and EBITDA of ₹12,372 (EBITDA margin 1.1%). Revenue has grown at a compounded annual rate (CAGR) of 17% over three years.
Company details
Contact details
Ravimine Pharma Private Limited's registered office is in Muzaffarpur, Bihar. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressMaripur Muzaffarpur 1 Muzaffarpur Bihar India, Bihar, India – 842003
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Ravimine Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Ravimine Pharma is trade. In detail, this covers wholesale trading.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading |
To see the full business activity and turnover split of Ravimine Pharma Private Limited, buy the company report.
Financials of Ravimine Pharma Private Limited
FY 2023 filings availableRavimine Pharma Private Limited reported revenue of ₹10.92 Lakh (up 60% YoY) for FY 2023.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 17% over three years, including 60% growth in the latest year. EBITDA fell 9% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | ₹10.92 Lakh | ||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹12,372 | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹5,707 | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 | FY 2018-19 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 1.1% | ||||
| Net Profit Margin | 0.5% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Ravimine Pharma Private Limited, buy the company report.
Board of directors of Ravimine Pharma Private Limited
Ravimine Pharma has 2 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Meera Kumari | Additional Director | 16 Jul 2020 | 6 Years 3 Months | Current |
| Sippy Shawarna | Director | 24 Jan 2018 | 8 Years 9 Months | Current |
Peer comparison
Ravimine Pharma Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (wholesale trading), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Atp Energy Solution Private Limited | ₹10.92 Lakh (FY 2025) | -76.0% | New Delhi, Delhi, India | |||
| Kmedlan Pharmaceuticals Private Limited | ₹10.92 Lakh (FY 2022) | Bilaspur, Chhattisgarh, India | ||||
| Prahar Chemicals (OPC) Private Limited | ₹10.92 Lakh (FY 2025) | -57.0% | Ernakulam, Kerala, India | |||
| Borassus Healthcare Private Limited | ₹10.92 Lakh (FY 2024) | 157.0% | Nanganallur, Tamil Nadu, India | |||
| JSM Associates Private Limited | ₹10.92 Lakh (FY 2020) | Gurgaon, Haryana, India | ||||
| Ravimine Pharma Private Limitedthis company | ₹10.92 Lakh (FY 2023) | ₹5,707 | 0.5% | 60.0% | Muzaffarpur, Bihar, India | |
| Eleganc Moduler System Private Limited | ₹10.92 Lakh (FY 2025) | -84.0% | Greater Noida, Uttar Pradesh, India | |||
| Daysha Retail Services Private Limited | ₹10.92 Lakh (FY 2025) | Chandigarh, India | ||||
| Salasar Vincom Private Limited | ₹10.92 Lakh (FY 2025) | 5.0% | Howrah, West Bengal, India | |||
| Smartworld Combine Network Private Limited | ₹10.92 Lakh (FY 2017) | 2098.0% | Indore, Madhya Pradesh, India | |||
| Foresight Biotech Private Limited | ₹10.92 Lakh (FY 2024) | 285.0% | New Delhi, Delhi, India |
To see the full peer comparison of Ravimine Pharma Private Limited, buy the company report.
Auditor
Ravimine Pharma Private Limited is audited by R M ASSOCIATES for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| R M ASSOCIATES | FY 2023 | 0307011C |
Shareholding
The shareholding of Ravimine Pharma Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Ravimine Pharma Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Ravimine Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Ravimine Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Ravimine Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 10AAICR7403H1ZP | Bihar | Active | 17 Mar 2018 |
To see the full GST registrations and return filing status of Ravimine Pharma Private Limited, buy the company report.
Recent activity
Ravimine Pharma Private Limited has 4 board changes on record since 2018: 2 appointments and 2 cessations. The latest: Alok Kaushal ceased to be Additional Director on 17 Jul 2020.
Frequently asked questions
Ravimine Pharma is an active private limited company based in Muzaffarpur, Bihar, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 January 2018 (8+ years old) and is registered under CIN U74999BR2018PTC036999.
Ravimine Pharma has 2 current directors:
- Meera Kumari - Additional Director
- Sippy Shawarna - Director
The latest financial statements of Ravimine Pharma on record with the MCA are for the year ended 31 March 2023. Its last annual general meeting was held on 30 September 2023. Year-wise statements from FY 2018 are in the company report.
The GSTIN of Ravimine Pharma is 10AAICR7403H1ZP, registered in Bihar.
The CIN (Corporate Identification Number) of Ravimine Pharma is U74999BR2018PTC036999. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Ravimine Pharma was incorporated on 24 January 2018, making it 8+ years old. It is registered with the Registrar of Companies, Patna.
The peers of Ravimine Pharma by revenue are Atp Energy Solution Private Limited, Kmedlan Pharmaceuticals Private Limited, Prahar Chemicals (OPC) Private Limited, Borassus Healthcare Private Limited, JSM Associates Private Limited and 5 more, all in the same principal business activity (wholesale trading).
Alok Kaushal ceased to be Additional Director on 17 Jul 2020. Meera Kumari was appointed as Additional Director on 16 Jul 2020. Sanjeev Kumar Singh ceased to be Director on 15 Feb 2020. Ravimine Pharma has 4 board changes on record in total.
The registered office of Ravimine Pharma is at Maripur Muzaffarpur 1 Muzaffarpur Bihar India, Bihar, India – 842003.
Ravimine Pharma operates in the pharma industry, in the drug formulation and development segment.
Ravimine Pharma can be reached at its registered office: Maripur Muzaffarpur 1 Muzaffarpur Bihar India, Bihar, India – 842003.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
